- Acerus Pharmaceuticals Corporation (ASP) signs an agreement with Verity Pharmaceuticals for the exclusive rights to promote Natesto in Puerto Rico
- Natesto is a prescription medicine that contains testosterone and is used to treat adult males who have low or no testosterone
- Verity Pharma will promote Natesto across the island of Puerto Rico to leverage its existing commercial footprint and health care network
- Acerus will maintain control of distribution, market access, and regulatory activities
- Acerus Pharmaceuticals Corporation (ASP) is up 14.29 per cent and is trading at $0.04 per share as of 2:58 p.m. EST
Acerus Pharmaceuticals Corporation (ASP) signs an agreement with Verity Pharmaceuticals for the exclusive rights to promote Natesto in Puerto Rico.
Natesto is a prescription medicine that contains testosterone and is used to treat adult males who have low or no testosterone.
Verity Pharma will promote Natesto across the island of Puerto Rico to leverage its existing commercial footprint and health care network.
Acerus will maintain control of distribution, market access, and regulatory activities.
Edward Gudaitis, President and CEO of Acerus, commented,
“Verity Pharma’s established and significant salesforce and healthcare network in Puerto Rico will be the catalyst to expand patient access to Natesto.”
Howard Glase, CEO of Verity Pharma, said Natesto offers ‘significant value’ to patients suffering from hypogonadism.
Verity Pharma is a privately-owned pharmaceutical company with offices in Canada, the United States, and Ireland.
The company specializes in providing innovative, market-leading pharmaceutical products to patients across North America.
Acerus is a Canadian-based specialty pharmaceutical company with a primary focus in the field of men’s health.
The company commercializes its products via its own salesforce in the U.S., Canada, and through a global network of licensed distributors in other territories.
Acerus Pharmaceuticals Corporation (ASP) is up 14.29 per cent and is trading at $0.04 per share as of 2:58 p.m. EST.
